Long non-coding rna lipter preserves lipid metabolism of the human heart
AssigneeThe Trustees of Indiana University
InventorLei YANG
Life of this patent
Estimating the term…
Abstract
Compositions and methods are disclosed for treating metabolic syndrome-associated heart disease cardiomyopathy and/or heart failure, wherein the method comprises the step of increasing the concentration of LIPTER RNA in the cardiomyocytes of said patient.
Claims22
A method of preserving cardiomyocyte function in a patient, said method comprising enhancing the concentration of LIPTER RNA in said cardiomyocytes (CMS).
(canceled)
(canceled)
A method of identifying subjects with abnormal lipid metabolism, said method comprising the steps of
- measuring LIPTER expression levels in a test subject's cells;
- comparing the detected LIPTER expression levels to the levels found in healthy subjects;
- identifying a test subject with abnormal lipid metabolism when the detected LIPTER expression levels are lower than the levels found in healthy subjects.
A method of treating subjects identified as having abnormal lipid metabolism, said method comprising the steps of
- measuring LIPTER expression levels in a test subject's cells;
- comparing the detected LIPTER expression levels to the levels found in healthy subjects;
- identifying a test subject with abnormal lipid metabolism when the detected LIPTER expression levels are lower than the levels found in healthy subjects
- treating said identified test subjects using standard therapies for heart disease optionally including the administration of therapeutic agents to increase LIPTER RNA levels in the subject's cardiomyocytes.
Dependencies are inferred from the claim text.